Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING), highlighting the company's progress toward a potential commercial launch of CTx-1301 for ADHD. The update follows Cingulate's fourth-quarter 2025 results and underscores the regulatory focus on manufacturing (CMC) rather than clinical performance, with the New Drug Application (NDA) remaining under FDA review via the 505(b)(2) pathway.
According to the announcement, the FDA's feedback has been limited to manufacturing and CMC issues, with no safety or efficacy concerns identified. This positions the remaining work as addressable process validation rather than clinical risk, suggesting that approval remains likely despite potential timing shifts. The company's recent financing, intellectual property progress, and commercial buildout efforts are supportive of the broader investment thesis.
Following a $12 million PIPE completed in February 2026, Cingulate has a pro forma cash balance of approximately $23 million, which Stonegate estimates provides runway into late 2026. Combined with ongoing access to capital through its ATM and ELOC facilities, the company is positioned to fund ongoing regulatory and manufacturing activities as it works toward resolution of remaining CMC items.
The large ADHD market opportunity presents significant potential for CTx-1301. According to the company, capturing just a 1% market share would imply approximately $250 million in revenue potential, primarily targeting the booster-dose segment. The full announcement, including downloadable images and bios, is available here.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services for public and private companies.
